Profil bibliographique

Ana Amorim

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

31Publications signalées

696Citations signalées

1Affiliations récentes

Les institutions déclarées

Center for Pediatric Endocrinology Zurich

Les domaines associés

T-cell and B-cell ImmunologyImmune Cell Function and InteractionImmunotherapy and Immune ResponsesNeuroinflammation and Neurodegeneration MechanismsMicroRNA in disease regulation

Les publications récentes

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. S7 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

Schematic detailing and results from the in vivo study with EMT6 tumor model treated with DP47-LTBR and FAP-LTBR molecules.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S2 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

Details of the tumor volumes and Tumor vs Stromal content of selected tumors used for spatial transcriptomics.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. S3 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

Schematic representation of the study design described in Figure 4 and 5. Average relative expression levels across samples for top differentially expressed genes in muFAP-LTBR vs control treatment.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S3 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

List of differentially regulated genes upon treatment with FAP-LTBR.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. S4 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

Differential gene expression results upon muFAP-LTBR treatment in stromal or tumor regions.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. S1 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

Immunofluorescence of the perfusable 3D vessel model showing surface expression of ICAM expression and chemokine secretion.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. S5 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

Estimated cell type abundance for selected cell types for two muFAP-LTBR treated samples. Spatial colocalization between HEVs and other cell types.

0 citations

Accès ouvert 2026 other OpenAlex

Data from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

AbstractPurpose: Immune checkpoint inhibitors (CPI) have revolutionized cancer therapy, yet many patients derive limited benefit because of poor immune infiltration within the tumor microenvironment (TME). The presence of tertiary lymphoid structures (TLS) and high endothelial venules (HEV) correlates with improved immunotherapy responses. …

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. S9 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

Schematic detailing and results from the in vivo study with BC004 tumor model in humanized mice treated with FAP-LTBR and FolR1 TCB in monotherapy and in combination.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Results S1 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

Method and results from the Cynomolgus study.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. S6 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

images show accumulation of T cells around HEVs in the muFAP-LTBR treated mice bearing AKPS CRC tumors.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S4 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors

Roberta Bianchi, Leo Kunz, Ralf J. Hosse, Michelle Brydon et autres

changes in abundance of various cell populations in tumors upon treatment with FAP-LTBR.

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.